Management of Hypercalcemia of Malignancy

Malignancy is one of the most common causes of hypercalcemia, particularly in cancer associated with bone metastases. Hypercalcemia occurs in up to 20% to 30% of cancer patients at some time during the course of their disease. Clinical manifestations of hypercalcemia vary in calcium level in blood. Signs and symptoms of hypercalcemia occur when the serum calcium level rises above those ranges. Fluids are first-line treatment with hypercalcemia followed by bisphosphanates if the calcium is high and the patient is experiencing symptoms. Various other medications are used as second-line agents in hypercalcemia of malignancy.

[1]  Michael C. Cotugno,et al.  Denosumab in hypercalcemia of malignancy: A case series , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[2]  S. Sundar,et al.  Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy , 2014, BMJ Case Reports.

[3]  A. F. Stewart Hypercalcemia Associated with Cancer , 2005 .

[4]  D. Schade,et al.  A practical approach to hypercalcemia. , 2003, American family physician.

[5]  Thomas E. Hughes,et al.  Gallium Nitrate , 1992, The Annals of pharmacotherapy.

[6]  Mimi I Hu Hypercalcemia of Malignancy: Current & Future Directions , 2012 .

[7]  A. Osborne Zoledronic acid , 2012, Reactions Weekly.